Loading…
HHS released a draft interim enforcement-discretion policy covering certain patient-specific 503A compounding of peptides, naming KPV among six peptide bulk substances. FDA rulemaking on the topic continues.
This is a human health peptide policy story with no link to feed ingredient supply, demand or prices.
prunderground.comLee BrockNov 12, 2026Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.
